Dr. Anton Bilchik Applauds New Pancreatic Cancer Treatments

SANTA MONICA, CA – Dr. Anton Bilchik, one of America's foremost cancer surgeons and researchers, wants to celebrate the achievements that have been made recently in the fight against pancreatic cancer, most notably several new studies for the first time show a combination of two or more new drugs prolong survival in patients with more advanced pancreatic cancer.

Biopharmaceutical manufacturers Celgene have announced that they are in the final stages of testing a new chemotherapy drug called Abraxane that, when given to patients with metastatic pancreas cancer in tandem with the existing drug gemcitabine, has been shown to extend the lives of many patients. The study found that the combination of gemcitabine and Abraxane (paclitaxel protein-bound particles for injectable suspension) produced a 59% increase in one year survival rates and a 225% increase in two-year survival rates – dramatic numbers for what is considered one of the most aggressive and potentially fatal types of cancer.

Dr. Bilchik has been practicing medicine for over 28 years and is considered one of the foremost experts on the disease in the country. He has been recognized as one of America's Top Cancer Doctors in each of the last 10 years and is the founder of the California Oncology Research Institute and Chief of Gastrointestinal Research at the John Wayne Cancer Institute at Saint John's Health Center.

To read more about Dr. Bilchik, pancreatic and other forms of cancer, and get other health tips and information, visit www.AntonBilchikMD.com. You can also contact the John Wayne Cancer Institute directly at http://www.newsaintjohns.org/John_Wayne_Cancer_Institute or (310) 449-5206.